effect of alpha blockers in benign prostatic hyperplasia

Not yet recruiting

Conditions: Benign prostatic hyperplasia withlower urinary tract symptoms,

Registration Number: CTRI/2021/04/033122

Lead Sponsor: DR I C VIGNESH RAJA

Brief Summary: In aging males lower urinary tract symptoms (LUTS) are a common problem and the most common cause for LUTS in elderly men is benign prostatic hyperplasia.Benign prostatic hyperplasia (BPH) is defined as a non malignant enlargement of the prostate associated with aging. In this condition the overgrowth of prostate tissue pushes against the urethra and the bladder, blocking the flow of urine. Clinical manifestations include obstruction in urine flow, discomfort and pain during urination.Prevalence of BPH is more between 50 to 70 yrs male and it accounts nearly 8% of men aged between 45 - 50 years and when men cross 80 years of age the prevalence rate is almost 80%.The treatment depends on the severity of symptoms. Management approaches range from observation only, to medical therapy, to minimally invasive, endoscopic or open surgery. Medical therapy works by reducing dynamic and static components. Alpha1a adrenergic receptor inhibition with selective (tamsulosin, silodosin, terazosin, alfuzosin) or non-selective (prazosin) drugs treat the dynamic component of benign prostatic hyperplasia. Among themSelective alpha 1 adrenergic antagonist are the first line drugs in the medical management of BPH.Tamsulosin blocks alpha 1 receptors in smooth muscles both in bladder neck and prostate which leads to relaxation and subsequently less resistance to urinary flow. Silodosin is a newer drug and it is a selective antagonist of post synaptic alpha 1 adrenoreceptors, which are located in human prostate, bladder base, bladder neck and prostatic urethra. Blockade of these alpha 1 adrenoreceptors can cause smooth muscles in the tissues to relax, resulting in an improvement in urine flow and reduction in BPH symptoms.The current study aimed to determine the effectiveness and adverse effects of silodosin with comparison of tamsulosin in symptomatic BPH

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: Male

Target Recruitment: 80

Inclusion Criteria

Benign prostatic hyperplasia with international prostatic symptom score above 7 Patient on silodosin Patient on tamsulosin willing to give informed consent.

Exclusion Criteria

Prostate carcinoma Patients with concomitant HIV, HBV or HCV Renal failure Liver disease Patient planned for cataract surgery.
Psychiatry patients.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
reduction in IPSS	4th week \| 8th week

Secondary Outcome Measures

Name	Time	Method
adverse drug reactions	4th week

Trial Locations

Locations (1): DHANALAKSHMI SRINIVASAN MEDICAL COLLEGE HOSPITAL
🇮🇳
Perambalur, TAMIL NADU, India
DHANALAKSHMI SRINIVASAN MEDICAL COLLEGE HOSPITAL
🇮🇳Perambalur, TAMIL NADU, India
DR I C VIGNESH RAJA
Principal investigator
9443080854
vigneshraja36@gmail.com